Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study

Jang, Yoon Ok; Kim, Young Ju; Baik, Soon Koo; Kim, Moon Young; Eom, Young Woo; Cho, Mee Yon; Park, Hong Jun; Park, So Yeon; Kim, Bo Ra; Kim, Jae Woo; Kim, Hyun Soo; Kwon, Sang Ok; Choi, Eun Hee; Kim, Yong Man

doi:10.1111/liv.12218

Cited by 168 publications

(169 citation statements)

References 33 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…In the field of liver cirrhosis, as shown in Table 1, many autologous [70][71][72][73][74][75][76][77][78][79][80][81][82][83] and four allogeneic [59][60][61][62] MSC therapies involving a variety of tissue origins and administration routes have been reported. Although details regarding the mechanisms of therapeutic effects in humans remain unclear, most studies have reported favorable effects with improvement in MELD scores, Child-Pugh scores, and some serum markers such as albumin and bilirubin.…”

Section: Mscsmentioning

confidence: 99%

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Terai

Tsuchiya

2016

J Gastroenterol

View full text Add to dashboard Cite

The treatment of liver cirrhosis is currently being standardized and developed specifically to reduce activation of hepatic stellate cells (HSCs), inhibit fibrosis, increase degradation of matrix components, and reduce activated myofibroblasts. Cell therapy can be applied in the treatment of liver cirrhosis; however, the characteristic features of this therapy differ from those of other treatments because of the involvement of a living body origin and production of multiple cytokines, chemokines, matrix metalloproteinases (MMPs), and growth factors. Thus, cell therapies can potentially have multiple effects on the damaged liver, including alleviating liver cirrhosis and stimulating liver regeneration with affecting the host cells. Cell therapies initially involved autologous bone marrow cell infusion, and have recently developed to include the use of specific cells such as mesenchymal stem cells and macrophages. The associated molecular mechanisms, routes of administration, possibility of allogeneic cell therapy, and host conditions appropriate for cell therapies are now being extensively analyzed. In this review, we summarize the status and future prospects of cell therapy for liver cirrhosis.

show abstract

Section: Mscsmentioning

confidence: 99%

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Terai

Tsuchiya

2016

J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…In a clinical trial performed by Jang et al (29), 11 patients with biopsy-proven alcoholic cirrhosis were twice transplanted BM-derived autologous MSCs via hepatic artery (29). They reported that in 6 of 11 patients, histological improvement was obtained.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis

Kantarcıoğlu

Demirci²,

Avcu³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: Because of several limitations and complications of liver transplantation, new alternative treatment modalities are required for patients with liver cirrhosis. Many study results encourage the use of autologous bone marrow-derived mesenchymal stem cells for liver diseases. In this study, we assessed the impact of autologous mesenchymal stem cell transplantation on liver tissue and liver chemistry. Materials and Methods: Twenty-five patients with biopsy-proven liver cirrhosis were enrolled in the study. Patients received 1×10 6 autologous mesenchymal stem cells/kg via a peripheral vein. Biochemical parameters were checked monthly. Periodical radiological screening and liver biopsies before mesenchymal stem cell transplantation were performed after 6 months. Liver specimens were assessed by a pathologist. Results: No side effect was observed and the mesenchymal stem cell transplantation procedure was well tolerated. Twelve patients completed the study. In 8 patients, improvements in Model for End-Stage Liver Disease (MELD) scores were observed. Serum albumin levels markedly increased in the third month. In patients with nonresponder hepatitis C, HCV RNA levels both became negative after mesenchymal stem cell transplantation. Histopathological examinations of liver tissues before and at 6 months after transplantation revealed no change in liver tissue regeneration or fibrosis. However, in 5 patients, hepatitis activity index scores decreased. Conclusion: Autologous mesenchymal stem cell transplantation via peripheral vein is safe and feasible. Consecutive liver biopsy examinations suggested that mesenchymal stem cells could not reach the liver in a sufficient amount. Improvement in patients and clearance of HCV RNA may have occurred through immunomodulatory mediators secreted by transplanted mesenchymal stem cells, namely the "endocrine" effect.

show abstract

“…Тем не менее, в большинстве недавних кли-нических испытаний используются МСК [38][39][40][41]. Так, Chernykh и соавт [38], как и другие исследователи [39][40][41], использовали аутоло-гичные МСК из костного мозга для терапии спинальной травмы.…”

Section: мск для терапии псмтunclassified

“…Так, Chernykh и соавт [38], как и другие исследователи [39][40][41], использовали аутоло-гичные МСК из костного мозга для терапии спинальной травмы. Когда исследователи сравнили клинические результаты с контроль-ной группой, они сообщили об улучшении по-казателей по шкалам ASIA, Barthel и Ashworth у 66% пациентов [38].…”

Section: мск для терапии псмтunclassified

Cell Therapy of Stroke and Spinal Cord Injury Complications

Konoplyannikov¹,

Baklaushev²,

Kalsin³

et al. 2015

Journal of Clinical Practice

View full text Add to dashboard Cite

е!ь …%" В обзоре анализируется современное состояние проблемы клеточной терапии неврологи-ческих осложнений ишемического инсульта и позвоночно-спинномозговой травмы (ПСМТ). Приводятся современные данные по использованию различных типов стволовых клеток для терапии данных тяжелых нарушений, полученные как в экспериментальных исследованиях на животных моделях, так и в результате клинических исследований. Наиболее подробно рассма-тривается применение мезенхимальных стволовых клеток (МСК) и нейральных стволовых/ прогениторных клеток (НСК/НПК) для терапии инсульта и ПСМТ. Обсуждаются дальнейшие перспективы развития клеточной терапии указанных заболеваний.Ключевые слова: ишемический инсульт, позвоночно-спинномозговая травма, стволовые клет-ки, мезенхимальные стволовые клетки, нейральные стволовые/прогениторные клетки. CELL THERAPY OF STROKE AND SPINAL CORD INJURY COMPLICATIONSThe review analyzes the current advances of cell therapy for neurological complications of ischemic stroke and spinal cord injury (SCI). We demonstrate the most recent data on the use of different types of stem cells for the treatment of these severe damages, obtained both in experimental studies using animal models and in clinical studies. We particularly discuss the use of mesenchymal stem cells (MSC) and neural stem/progenitor cells (NSC/NPC) for the treatment of stroke and SCI. We also discuss the prospects for a further development of cell therapy of these diseases.

show abstract

Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study

Abstract: Bone marrow-derived mesenchymal stem cells therapy in alcoholic cirrhosis induces a histological and quantitative improvement of hepatic fibrosis.

Cited by 168 publications

References 33 publications

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis

Cell Therapy of Stroke and Spinal Cord Injury Complications

Contact Info

Product

Resources

About